Overview

Evaluation of CYP2C9 Activity

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9. The purpose of the present study is: 1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity 2. To correlate phenytoin metabolic ratio with CYP2C9 genotype 3. To study the frequency distribution of CYP2C9 activity in-vivo
Phase:
N/A
Details
Lead Sponsor:
Hadassah Medical Organization
Collaborator:
United States - Israel Binational Science Foundation
Treatments:
Phenytoin